1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions

Inclusion Criteria:

• Patients who met the inclusion criteria for entry into the Core study and who took at least one dose of study drug and have completed the CZOL446H2337 Core study
• Patients must be enrolled into the extension at visit 9 between 5 and 10 months after Visit 5 of the core study.
• Patients compliant with the regimen of calcium and vitamin D intake as required in the Core study (at least 800 mg calcium for 6-8 years of age or at least 1300 mg calcium for 9-19 years of age and 400 IU daily vitamin D, through diet or supplementation).
• Patient who signed the consent form to participate in the study.

Exclusion Criteria:

• Patients who demonstrated a major protocol violation in the core study
• Patients for whom the investigator considers participation in the extension study is not appropriate
• Hypocalcaemia: any value (age-matched) below the normal range at Visit 8
• Ionized Calcium below the normal range at Visit 9
• A new malignancy diagnosis during the Core study
• A new diagnosis of sarcoidosis during the Core study
• Non-ambulatory patients who require wheelchair assistance for mobility
• Any prior use of Bisphosphonates other than study drug during the Core study
• Active hyperparathyroidism or hyper/hypothyroidism during the Core study
• Any use of anabolic steroids or growth hormone for more than 3 months just prior to entering the extension
• Use of any other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
• History of hypersensitivity of any of the study drugs or the drugs of similar chemical classes.
• Women of child-bearing potential unless they use a highly effective method of birth control.

Other protocol-defined exclusion criteria may apply